全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

HMGB1 Is Involved in IFN-α Production and TRAIL Expression by HIV-1-Exposed Plasmacytoid Dendritic Cells: Impact of the Crosstalk with NK Cells

DOI: 10.1371/journal.ppat.1005407

Full-Text   Cite this paper   Add to My Lib

Abstract:

Plasmacytoid dendritic cells (pDCs) are innate sensors of viral infections and important mediators of antiviral innate immunity through their ability to produce large amounts of IFN-α. Moreover, Toll-like receptor 7 (TLR7) and 9 (TLR9) ligands, such as HIV and CpG respectively, turn pDCs into TRAIL-expressing killer pDCs able to lyse HIV-infected CD4+ T cells. NK cells can regulate antiviral immunity by modulating pDC functions, and pDC production of IFN-α as well as cell–cell contact is required to promote NK cell functions. Impaired pDC-NK cell crosstalk was reported in the setting of HIV-1 infection, but the impact of HIV-1 on TRAIL expression and innate antiviral immunity during this crosstalk is unknown. Here, we report that low concentrations of CCR5-tropic HIV-1Ba-L promote the release of pro-inflammatory cytokines such as IFN-α, TNF-α, IFN-γ and IL-12, and CCR5-interacting chemokines (MIP-1α and MIP-1β) in NK-pDCs co-cultures. At high HIV-1BaL concentrations, the addition of NK cells did not promote the release of these mediators, suggesting that once efficiently triggered by the virus, pDCs could not integrate new activating signals delivered by NK cells. However, high HIV-1BaL concentrations were required to trigger IFN-α-mediated TRAIL expression at the surface of both pDCs and NK cells during their crosstalk. Interestingly, we identified the alarmin HMGB1, released at pDC-NK cell synapse, as an essential trigger for the secretion of IFN-α and IFN-related soluble mediators during the interplay of HIV-1 exposed pDCs with NK cells. Moreover, HMGB1 was found crucial for mTRAIL translocation to the plasma membrane of both pDCs and NK cells during their crosstalk following pDC exposure to HIV-1. Data from serum analyses of circulating HMGB1, HMGB1-specific antibodies, sTRAIL and IP-10 in a cohort of 67 HIV-1+ patients argue for the in vivo relevance of these observations. Altogether, these findings identify HMGB1 as a trigger for IFN-α-mediated TRAIL expression at the surface of pDCs and NK cells, and they suggest a novel mechanism of innate control of HIV-1 infection.

References

[1]  Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–52. Epub 1998/04/01. doi: 10.1038/32588 pmid:9521319.
[2]  Moretta A, Marcenaro E, Sivori S, Della Chiesa M, Vitale M, Moretta L. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends in immunology. 2005;26(12):668–75. Epub 2005/10/04. doi: 10.1016/j.it.2005.09.008 pmid:16198147.
[3]  Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Current topics in microbiology and immunology. 2006;311:17–58. Epub 2006/10/20. pmid:17048704. doi: 10.1007/3-540-32636-7_2
[4]  Steinbrink K, Mahnke K, Grabbe S, Enk AH, Jonuleit H. Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance? Human immunology. 2009;70(5):289–93. Epub 2009/02/17. doi: 10.1016/j.humimm.2009.02.003 pmid:19217922.
[5]  Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell. 2001;106(3):263–6. Epub 2001/08/18. pmid:11509174. doi: 10.1016/s0092-8674(01)00455-x
[6]  Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell. 2001;106(3):259–62. Epub 2001/08/18. pmid:11509173. doi: 10.1016/s0092-8674(01)00456-1
[7]  Gary-Gouy H, Lebon P, Dalloul AH. Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 2002;22(6):653–9. Epub 2002/08/07. doi: 10.1089/10799900260100132 pmid:12162875.
[8]  Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood. 2005;106(7):2252–8. Epub 2005/06/04. doi: 10.1182/blood-2005-03-1154 pmid:15933055.
[9]  Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nature medicine. 1999;5(4):405–11. Epub 1999/04/15. doi: 10.1038/7403 pmid:10202929.
[10]  Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med. 2002;195(3):335–41. Epub 2002/02/06. pmid:11828008; PubMed Central PMCID: PMC2193592. doi: 10.1084/jem.20010934
[11]  Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood. 2004;104(10):3267–75. Epub 2004/07/10. doi: 10.1182/blood-2004-01-0380 pmid:15242871.
[12]  Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, Carra G, et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. Journal of immunology. 2005;174(2):727–34. Epub 2005/01/07. pmid:15634892. doi: 10.4049/jimmunol.174.2.727
[13]  Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. The Journal of experimental medicine. 2002;195(3):327–33. Epub 2002/02/06. pmid:11828007; PubMed Central PMCID: PMC2193595. doi: 10.1084/jem.20010938
[14]  Della Chiesa M RC, Thiel A, Moretta L, Moretta A. Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte-derived dendritic cells during innate immune responses. Blood. 2006;108(12):3851–8. pmid:16873676 doi: 10.1182/blood-2006-02-004028
[15]  Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nature reviews Immunology. 2002;2(12):957–64. doi: 10.1038/nri956 pmid:12461568.
[16]  Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood. 2003;101(11):4505–11. Epub 2003/02/11. doi: 10.1182/blood-2002-10-3189 pmid:12576311.
[17]  Barron MA, Blyveis N, Palmer BE, MaWhinney S, Wilson CC. Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. The Journal of infectious diseases. 2003;187(1):26–37. Epub 2003/01/01. doi: 10.1086/345957 pmid:12508143.
[18]  Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood. 2005;106(10):3366–9. doi: 10.1182/blood-2005-03-1100 pmid:16002429.
[19]  Reitano KN, Kottilil S, Gille CM, Zhang X, Yan M, O'Shea MA, et al. Defective plasmacytoid dendritic cell-NK cell cross-talk in HIV infection. AIDS research and human retroviruses. 2009;25(10):1029–37. Epub 2009/10/03. doi: 10.1089/aid.2008.0311 pmid:19795986; PubMed Central PMCID: PMC2828160.
[20]  Conry SJ, Milkovich KA, Yonkers NL, Rodriguez B, Bernstein HB, Asaad R, et al. Impaired plasmacytoid dendritic cell (PDC)-NK cell activity in viremic human immunodeficiency virus infection attributable to impairments in both PDC and NK cell function. Journal of virology. 2009;83(21):11175–87. doi: 10.1128/JVI.00753-09 pmid:19692459; PubMed Central PMCID: PMC2772797.
[21]  Benlahrech A, Gotch F, Kelleher P, Patterson S. Loss of NK stimulatory capacity by plasmacytoid and monocyte-derived DC but not myeloid DC in HIV-1 infected patients. PloS one. 2011;6(3):e17525. doi: 10.1371/journal.pone.0017525 pmid:21408163; PubMed Central PMCID: PMC3050890.
[22]  Mondelli MU, Oliviero B, Mele D, Mantovani S, Gazzabin C, Varchetta S. Natural killer cell functional dichotomy: a feature of chronic viral hepatitis? Frontiers in immunology. 2012;3:351. doi: 10.3389/fimmu.2012.00351 pmid:23420385; PubMed Central PMCID: PMC3572686.
[23]  Hardy AW, Graham DR, Shearer GM, Herbeuval JP. HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(44):17453–8. Epub 2007/10/25. doi: 10.1073/pnas.0707244104 pmid:17956986; PubMed Central PMCID: PMC2077277.
[24]  Gougeon ML, Herbeuval JP. IFN-alpha and TRAIL: a double edge sword in HIV-1 disease? Experimental cell research. 2012;318(11):1260–8. doi: 10.1016/j.yexcr.2012.03.012 pmid:22480868.
[25]  Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. The Journal of experimental medicine. 1999;189(9):1451–60. pmid:10224285; PubMed Central PMCID: PMC2193058. doi: 10.1084/jem.189.9.1451
[26]  Vidalain PO, Azocar O, Lamouille B, Astier A, Rabourdin-Combe C, Servet-Delprat C. Measles virus induces functional TRAIL production by human dendritic cells. Journal of virology. 2000;74(1):556–9. pmid:10590149; PubMed Central PMCID: PMC111571. doi: 10.1128/jvi.74.1.556-559.2000
[27]  Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. European journal of immunology. 2001;31(11):3138–46. pmid:11745330. doi: 10.1002/1521-4141(200111)31:11<3138::aid-immu3138>3.0.co;2-b
[28]  Herbeuval JP, Boasso A, Grivel JC, Hardy AW, Anderson SA, Dolan MJ, et al. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood. 2005;105(6):2458–64. Epub 2004/12/09. doi: 10.1182/blood-2004-08-3058 pmid:15585654.
[29]  Gasper-Smith N, Crossman DM, Whitesides JF, Mensali N, Ottinger JS, Plonk SG, et al. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. Journal of virology. 2008;82(15):7700–10. doi: 10.1128/JVI.00605-08 pmid:18508902; PubMed Central PMCID: PMC2493338.
[30]  Herbeuval JP, Nilsson J, Boasso A, Hardy AW, Vaccari M, Cecchinato V, et al. HAART reduces death ligand but not death receptors in lymphoid tissue of HIV-infected patients and simian immunodeficiency virus-infected macaques. Aids. 2009;23(1):35–40. doi: 10.1097/QAD.0b013e32831cb907 pmid:19050384.
[31]  Miura Y, Misawa N, Maeda N, Inagaki Y, Tanaka Y, Ito M, et al. Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice. The Journal of experimental medicine. 2001;193(5):651–60. pmid:11238596; PubMed Central PMCID: PMC2193390. doi: 10.1084/jem.193.5.651
[32]  Herbeuval JP, Grivel JC, Boasso A, Hardy AW, Chougnet C, Dolan MJ, et al. CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood. 2005;106(10):3524–31. Epub 2005/07/28. doi: 10.1182/blood-2005-03-1243 pmid:16046522; PubMed Central PMCID: PMC1895067.
[33]  Melki MT, Saidi H, Dufour A, Olivo-Marin JC, Gougeon ML. Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk—a pivotal role of HMGB1. PLoS pathogens. 2010;6(4):e1000862. Epub 2010/04/27. doi: 10.1371/journal.ppat.1000862 pmid:20419158; PubMed Central PMCID: PMC2855334.
[34]  Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. Journal of leukocyte biology. 2013;93(6):865–73. Epub 2013/03/01. doi: 10.1189/jlb.1212662 pmid:23446148; PubMed Central PMCID: PMC4051189.
[35]  Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248–51. pmid:10398600. doi: 10.1126/science.285.5425.248
[36]  Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H, et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature. 2009;462(7269):99–103. doi: 10.1038/nature08512 pmid:19890330.
[37]  Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nature immunology. 2007;8(5):487–96. Epub 2007/04/10. doi: 10.1038/ni1457 pmid:17417641.
[38]  Dumitriu IE, Baruah P, Bianchi ME, Manfredi AA, Rovere-Querini P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. European journal of immunology. 2005;35(7):2184–90. Epub 2005/05/26. doi: 10.1002/eji.200526066 pmid:15915542.
[39]  Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. Journal of immunology. 2004;173(1):307–13. pmid:15210788. doi: 10.4049/jimmunol.173.1.307
[40]  Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. Journal of leukocyte biology. 2007;81(1):84–91. doi: 10.1189/jlb.0306171 pmid:17035340.
[41]  Semino C, Angelini G, Poggi A, Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood. 2005;106(2):609–16. doi: 10.1182/blood-2004-10-3906 pmid:15802534.
[42]  Nowak P, Barqasho B, Sonnerborg A. Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection. Aids. 2007;21(7):869–71. doi: 10.1097/QAD.0b013e3280b079b6 pmid:17415043.
[43]  Saidi H, Melki MT, Gougeon ML. HMGB1-dependent triggering of HIV-1 replication and persistence in dendritic cells as a consequence of NK-DC cross-talk. PloS one. 2008;3(10):e3601. Epub 2008/11/01. doi: 10.1371/journal.pone.0003601 pmid:18974890; PubMed Central PMCID: PMC2571988.
[44]  Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. The Journal of experimental medicine. 2000;192(2):219–26. pmid:10899908; PubMed Central PMCID: PMC2193254. doi: 10.1084/jem.192.2.219
[45]  Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annual review of immunology. 2005;23:275–306. Epub 2005/03/18. doi: 10.1146/annurev.immunol.23.021704.115633 pmid:15771572.
[46]  Lim HD, Istyastono EP, van de Stolpe A, Romeo G, Gobbi S, Schepers M, et al. Clobenpropit analogs as dual activity ligands for the histamine H3 and H4 receptors: synthesis, pharmacological evaluation, and cross-target QSAR studies. Bioorganic & medicinal chemistry. 2009;17(11):3987–94. doi: 10.1016/j.bmc.2009.04.007 pmid:19414267.
[47]  Mazzoni A, Leifer CA, Mullen GE, Kennedy MN, Klinman DM, Segal DM. Cutting edge: histamine inhibits IFN-alpha release from plasmacytoid dendritic cells. Journal of immunology. 2003;170(5):2269–73. pmid:12594246. doi: 10.4049/jimmunol.170.5.2269
[48]  Megjugorac NJ, Young HA, Amrute SB, Olshalsky SL, Fitzgerald-Bocarsly P. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. Journal of leukocyte biology. 2004;75(3):504–14. Epub 2004/01/27. doi: 10.1189/jlb.0603291 pmid:14742635.
[49]  Piqueras B, Connolly J, Freitas H, Palucka AK, Banchereau J. Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood. 2006;107(7):2613–8. Epub 2005/12/01. doi: 10.1182/blood-2005-07-2965 pmid:16317096; PubMed Central PMCID: PMC1895384.
[50]  Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19(2):225–34. pmid:12932356. doi: 10.1016/s1074-7613(03)00208-5
[51]  Decalf J, Fernandes S, Longman R, Ahloulay M, Audat F, Lefrerre F, et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. The Journal of experimental medicine. 2007;204(10):2423–37. doi: 10.1084/jem.20070814 pmid:17893202; PubMed Central PMCID: PMC2118448.
[52]  Thomas JM, Pos Z, Reinboth J, Wang RY, Wang E, Frank GM, et al. Differential responses of plasmacytoid dendritic cells to influenza virus and distinct viral pathogens. Journal of virology. 2014;88(18):10758–66. Epub 2014/07/11. doi: 10.1128/JVI.01501-14 pmid:25008918; PubMed Central PMCID: PMC4178854.
[53]  Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270(5243):1811–5. pmid:8525373. doi: 10.1126/science.270.5243.1811
[54]  Fonteneau JF, Larsson M, Beignon AS, McKenna K, Dasilva I, Amara A, et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. Journal of virology. 2004;78(10):5223–32. Epub 2004/04/29. pmid:15113904; PubMed Central PMCID: PMC400371. doi: 10.1128/jvi.78.10.5223-5232.2004
[55]  Fitzgerald-Bocarsly P, Jacobs ES. Plasmacytoid dendritic cells in HIV infection: striking a delicate balance. Journal of leukocyte biology. 2010;87(4):609–20. doi: 10.1189/jlb.0909635 pmid:20145197; PubMed Central PMCID: PMC2858309.
[56]  Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A, et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. Journal of immunology. 2003;170(9):4465–74. Epub 2003/04/23. pmid:12707322. doi: 10.4049/jimmunol.170.9.4465
[57]  Gougeon ML, Melki MT, Saidi H. HMGB1, an alarmin promoting HIV dissemination and latency in dendritic cells. Cell death and differentiation. 2012;19(1):96–106. doi: 10.1038/cdd.2011.134 pmid:22033335; PubMed Central PMCID: PMC3252828.
[58]  Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chemistry & biology. 2007;14(4):431–41. Epub 2007/04/28. doi: 10.1016/j.chembiol.2007.03.007 pmid:17462578.
[59]  Dave SH, Tilstra JS, Matsuoka K, Li F, DeMarco RA, Beer-Stolz D, et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. Journal of leukocyte biology. 2009;86(3):633–43. Epub 2009/05/21. doi: 10.1189/jlb.1008662 pmid:19454652; PubMed Central PMCID: PMC2735284.
[60]  Colisson R, Barblu L, Gras C, Raynaud F, Hadj-Slimane R, Pique C, et al. Free HTLV-1 induces TLR7-dependent innate immune response and TRAIL relocalization in killer plasmacytoid dendritic cells. Blood. 2010;115(11):2177–85. Epub 2009/12/17. doi: 10.1182/blood-2009-06-224741 pmid:20007807.
[61]  Barblu L, Machmach K, Gras C, Delfraissy JF, Boufassa F, Leal M, et al. Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferon-alpha and differentiate into functional killer pDCs under HIV activation. The Journal of infectious diseases. 2012;206(5):790–801. Epub 2012/06/14. doi: 10.1093/infdis/jis384 pmid:22693234.
[62]  Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. Journal of immunological methods. 2004;294(1–2):15–22. doi: 10.1016/j.jim.2004.08.008 pmid:15604012.
[63]  Herbeuval JP, Hardy AW, Boasso A, Anderson SA, Dolan MJ, Dy M, et al. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(39):13974–9. Epub 2005/09/22. doi: 10.1073/pnas.0505251102 pmid:16174727; PubMed Central PMCID: PMC1224361.
[64]  Wen Z, Xu L, Chen X, Xu W, Yin Z, Gao X, et al. Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. Journal of immunology. 2013;190(11):5411–22. doi: 10.4049/jimmunol.1203301 pmid:23616573.
[65]  Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. The Journal of experimental medicine. 2008;205(13):3007–18. doi: 10.1084/jem.20081165 pmid:19064698; PubMed Central PMCID: PMCPMC2605236.
[66]  Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther. 2011;13(3):R71. doi: 10.1186/ar3332 pmid:21548924; PubMed Central PMCID: PMCPMC3218880.
[67]  Wirestam L, Schierbeck H, Skogh T, Gunnarsson I, Ottosson L, Erlandsson-Harris H, et al. Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus. Arthritis Res Ther. 2015;17:338. doi: 10.1186/s13075-015-0856-2 pmid:26596890; PubMed Central PMCID: PMCPMC4657231.
[68]  Urbonaviciute V, Voll RE. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. J Intern Med. 2011;270(4):309–18. doi: 10.1111/j.1365-2796.2011.02432.x pmid:21793951.
[69]  Urbonaviciute V, Furnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, et al. Factors masking HMGB1 in human serum and plasma. Journal of leukocyte biology. 2007;81(1):67–74. doi: 10.1189/jlb.0306196 pmid:17060363.
[70]  Padovan E, Spagnoli GC, Ferrantini M, Heberer M. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. Journal of leukocyte biology. 2002;71(4):669–76. pmid:11927654.
[71]  Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. The Journal of clinical investigation. 2005;115(11):3265–75. Epub 2005/10/15. doi: 10.1172/JCI26032 pmid:16224540; PubMed Central PMCID: PMC1253628.
[72]  Lepelley A, Louis S, Sourisseau M, Law HK, Pothlichet J, Schilte C, et al. Innate sensing of HIV-infected cells. PLoS pathogens. 2011;7(2):e1001284. doi: 10.1371/journal.ppat.1001284 pmid:21379343; PubMed Central PMCID: PMC3040675.
[73]  Harrich D, Hooker B. Mechanistic aspects of HIV-1 reverse transcription initiation. Reviews in medical virology. 2002;12(1):31–45. Epub 2002/01/12. pmid:11787082. doi: 10.1002/rmv.339
[74]  Kleiman L, Halwani R, Javanbakht H. The selective packaging and annealing of primer tRNALys3 in HIV-1. Current HIV research. 2004;2(2):163–75. Epub 2004/04/14. pmid:15078180. doi: 10.2174/1570162043484988
[75]  Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nature immunology. 2003;4(10):1009–15. Epub 2003/09/23. doi: 10.1038/ni978 pmid:14502286.
[76]  Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L, et al. Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. Journal of immunology. 2004;172(9):5363–70. Epub 2004/04/22. pmid:15100276. doi: 10.4049/jimmunol.172.9.5363
[77]  Tilton JC, Manion MM, Luskin MR, Johnson AJ, Patamawenu AA, Hallahan CW, et al. Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro. Journal of virology. 2008;82(8):3997–4006. doi: 10.1128/JVI.01545-07 pmid:18256146; PubMed Central PMCID: PMC2293017.
[78]  Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nature reviews Immunology. 2007;7(6):454–65. doi: 10.1038/nri2093 pmid:17525754.
[79]  Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ, et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Molecular and cellular biology. 2009;29(17):4841–51. doi: 10.1128/MCB.00224-09 pmid:19564419; PubMed Central PMCID: PMC2725724.
[80]  Kang HK, Liu M, Datta SK. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. Journal of immunology. 2007;178(12):7849–58. Epub 2007/06/06. pmid:17548623. doi: 10.4049/jimmunol.178.12.7849
[81]  Diana J, Griseri T, Lagaye S, Beaudoin L, Autrusseau E, Gautron AS, et al. NKT cell-plasmacytoid dendritic cell cooperation via OX40 controls viral infection in a tissue-specific manner. Immunity. 2009;30(2):289–99. Epub 2009/02/17. doi: 10.1016/j.immuni.2008.12.017 pmid:19217323.
[82]  Saas P, Perruche S. Functions of TGF-beta-exposed plasmacytoid dendritic cells. Critical reviews in immunology. 2012;32(6):529–53. pmid:23428227. doi: 10.1615/critrevimmunol.2013005868
[83]  Tomescu C, Chehimi J, Maino VC, Montaner LJ. NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells. Journal of immunology. 2007;179(4):2097–104. Epub 2007/08/07. pmid:17675468. doi: 10.4049/jimmunol.179.4.2097
[84]  Hagberg N, Berggren O, Leonard D, Weber G, Bryceson YT, Alm GV, et al. IFN-alpha production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes is promoted by NK cells via MIP-1beta and LFA-1. Journal of immunology. 2011;186(9):5085–94. Epub 2011/03/25. doi: 10.4049/jimmunol.1003349 pmid:21430220.
[85]  Takahashi Y, Byrareddy SN, Albrecht C, Brameier M, Walter L, Mayne AE, et al. In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection. PLoS pathogens. 2014;10(3):e1003929. Epub 2014/03/08. doi: 10.1371/journal.ppat.1003929 pmid:24603870; PubMed Central PMCID: PMC3946395.
[86]  Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. Journal of internal medicine. 2004;255(3):332–43. Epub 2004/02/12. pmid:14871457. doi: 10.1111/j.1365-2796.2003.01296.x
[87]  Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. The EMBO journal. 2003;22(20):5551–60. Epub 2003/10/09. doi: 10.1093/emboj/cdg516 pmid:14532127; PubMed Central PMCID: PMC213771.
[88]  Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–5. Epub 2002/07/12. doi: 10.1038/nature00858 pmid:12110890.
[89]  Bell CW, Jiang W, Reich CF 3rd, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. American journal of physiology Cell physiology. 2006;291(6):C1318–25. Epub 2006/07/21. doi: 10.1152/ajpcell.00616.2005 pmid:16855214.
[90]  Bianchi ME. HMGB1 loves company. Journal of leukocyte biology. 2009;86(3):573–6. Epub 2009/05/06. doi: 10.1189/jlb.1008585 pmid:19414536.
[91]  Troseid M, Nowak P, Nystrom J, Lindkvist A, Abdurahman S, Sonnerborg A. Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy. Aids. 2010;24(11):1733–7. doi: 10.1097/QAD.0b013e32833b254d pmid:20502315.
[92]  Barqasho B, Nowak P, Abdurahman S, Walther-Jallow L, Sonnerborg A. Implications of the release of high-mobility group box 1 protein from dying cells during human immunodeficiency virus type 1 infection in vitro. J Gen Virol. 2010;91(Pt 7):1800–9. doi: 10.1099/vir.0.016915-0 pmid:20200191.
[93]  Gougeon ML. Apoptosis as an HIV strategy to escape immune attack. Nature reviews Immunology. 2003;3(5):392–404. doi: 10.1038/nri1087 pmid:12766761.
[94]  Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365–71. doi: 10.1038/nm1511 pmid:17115046.
[95]  Hardy AW, Graham DR, Shearer GM, Herbeuval JP. HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(44):17453–8. doi: 10.1073/pnas.0707244104 pmid:17956986; PubMed Central PMCID: PMCPMC2077277.
[96]  Schnepple DJ, Shepard B, Bren GD, Cummins NW, Natesampillai S, Trushin S, et al. Isolation of a TRAIL antagonist from the serum of HIV-infected patients. J Biol Chem. 2011;286(41):35742–54. doi: 10.1074/jbc.M111.274639 pmid:21859711; PubMed Central PMCID: PMCPMC3195643.
[97]  Saidi H, Magri G, Nasreddine N, Requena M, Belec L. R5- and X4-HIV-1 use differentially the endometrial epithelial cells HEC-1A to ensure their own spread: implication for mechanisms of sexual transmission. Virology. 2007;358(1):55–68. doi: 10.1016/j.virol.2006.07.029 pmid:16934308.
[98]  Pugliese P, Cuzin L, Cabie A, Poizot-Martin I, Allavena C, Duvivier C, et al. A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med. 2009;10(8):504–11. doi: 10.1111/j.1468-1293.2009.00719.x pmid:19486189.
[99]  Lecoeur H, Melki MT, Saidi H, Gougeon ML. Analysis of apoptotic pathways by multiparametric flow cytometry: application to HIV infection. Methods in enzymology. 2008;442:51–82. doi: 10.1016/S0076-6879(08)01403-1 pmid:18662564.
[100]  Launay O, Sadorge C, Jolly N, Poirier B, Bechet S, van der Vliet D, et al. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial. Vaccine. 2009;27(8):1184–91. doi: 10.1016/j.vaccine.2008.12.021 pmid:19135496.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133